The Philippine Association of Oral & Maxillofacial Surgeons , Inc. (PAOMS)
"Emerging Therapies with Potential Risk for Medication - Related to Jaw Osteonecrosis"
Angenine Alfafara, DMD,MSD
DMD , University of the Philippines
MSD , Department of Oral and Maxillofacial Surgery , Ewha University
Despite numerous investigations , the pathophysiology of medication - related osteonecrosis of the jaw ( MRONJ ) remains elusive . These lesions were first reported in 2003 and were associated with the use of bisphosphonates . However , more drugs exhibiting osteonecrotic effects have emerged and included anti - resorptives , anti angiogenics and some immune - modulators . Recently , Tocilizumab , a monoclonal antibody therapy , has gained attention for its experimental use in COVID - 19 treatment . As more patients receive these drugs , clinicians should be wary of their potential risk for MRONJ development and employ necessary preventive measures . This lecture provides a quick review of the emerging medications recently reported to be associated with MRONJ development.
SUNDAY
JUNE 6 , 2021
10:00 - 10:45 | Business Meeting ( PAOMFS )
11:00 - 12:00 | Lecture by Dr. Alfafara ( Accessible to all )
